A 22-year-old man was initially diagnosed with hypertrophic cardiomyopathy (HCM) at 19 years of age during longitudinal family screening. He had been fit, active, and without cardiovascular symptoms or limitations. There was no family history of sudden death. He completed 18 minutes on a standard Bruce exercise test with normal heart rate and blood pressure response. Maximal left ventricular wall thickness was 17 mm; there was no resting or exercise-provoked obstruction; the left atrial size was normal; and no ventricular ectopy was identified on ambulatory monitoring. Three years after the initial diagnosis, without change in any clinical features, he had a cardiac arrest while walking to the subway.
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Sudden death events in patients with HCM are rare, stochastic, and typically dissociated from premonitory changes in cardiac symptomatology, function, or morphology. Traditional risk predictors have low individual sensitivity and specificity. As a result, identifying patients who are at an increased risk for sudden cardiac death (SCD) remains a major clinical challenge. The stakes are high because, although implantable cardioverter-defibrillators (ICDs) can largely prevent SCD, they do not improve quality of life, and the long-term risks are real. The cumulative burden of infections, lead fractures, inappropriate shocks, and other complications will be particularly experienced by patients with HCM, who are usually younger than are other patients receiving ICDs and thus will potentially live with their devices for decades.
Large cohorts and iterative randomized controlled trials have evaluated SCD risk and were used to develop management guidelines in more common diseases such as ischemic and dilated cardiomyopathies. In contrast, for patients with HCM with a real but highly variable risk for SCD, our management is based only on relatively small retrospective cohort studies including patients largely cared for at tertiary care centers. Two major risk stratification systems have been developed over the past 20 years. The American College of Cardiology/American Heart Association guidelines were published in 2011, 1 and the European Society of Cardiology guidelines were published in 2014. 2 The US guidelines list 3 major risk factors for SCD: left ventricular wall thickness ≥30 mm, a family history of SCD caused by HCM, and a personal history of syncope. The guidelines indicate that ICD placement may be reasonable if any one of these major risk factors is present, stressing the need for shared decision making between physician and patient. Minor risk factors include nonsustained ventricular tachycardia (NSVT) and hypotensive response to exercise. If these minor risk factors are present together with a risk modifier such left ventricular outflow tract obstruction, extensive late gadolinium enhancement on magnetic resonance imaging, apical aneurysm, or genetic mutations with a potentially increased association with SCD, an ICD could be considered.
The European Society of Cardiology advocates a more quantitative approach to SCD prediction using a multivariable regression model (the calculations can be done by an online calculator) to generate a score that predicts the 5-year risk for SCD. 2 This model includes many of the same variables as the American guidelines but attempts to treat continuous variables such as maximal wall thickness and maximal left ventricular outflow tract gradient as continuous. However, family history and NSVT remain dichotomized as yes/no responses, although biologically, a graded effect may be anticipated, with higher risk conferred by a higher proportion of affected relatives experiencing sudden death or by a higher burden of ventricular ectopy than the triplet that would qualify a "yes" response to NSVT in the calculator. In addition, other variables such as age, left ventricular outflow tract gradient, and left atrial dimension are included in the calculator. In this model, patients are stratified into a low, intermediate, and high 5-year risk of SCD. High-risk individuals should be considered for ICD implantation, whereas ICDs can generally be avoided in low-risk individuals. Those who are at an intermediate risk merit a more individualized approach, considering the risks and benefits of ICD implantation and patient preferences.
Two prior publications with modest numbers of patients attempted to validate the 2014 European Society of Cardiology calculator with variable results. In the first, of 1629 patients with HCM, 35 had SCD events, but only 4 had scores indicating ≥6% 5-year risk for SCD on the European Society of Cardiology calculator. 3 Of the 46 with ICD-treated arrhythmias, only 12 had scores ≥6%. Low scores (<4%) were present in 21 of those with SCD and 27 of those with ICD-treated arrhythmias. 3 In the second publication, of 706 patients with HCM, SCD occurred in 42 (5.9%). The sensitivity (70%), specificity (69%), and C statistic (0.69) were similar to the 2014 derivation article. 4 The article by O'Mahony and colleagues 5 in this issue of Circulation seeks to validate the European risk calculator in an independent cohort of 3703 patients. Of these, 159 patients reached the SCD end point during a median 5.9-year follow-up (0.6%/y). However, a significant number had missing data, particularly in documenting NSVT (30%) and left ventricular outflow tract gradient (17%). Complete data were available for 2147 patients, and, in these patients, the annualized rate of SCD was 0.5%. Participants with complete data were grouped into 3 groups on the basis of how the model predicted their risk for SCD: low (<4% predicted 5-year risk of SCD), intermediate (4%-6%), and high (≥6%).
The 5-year incidence of SCD was low in the group predicted to be at a low risk (1.4% over 5 years; 0.3% annualized rate of SCD) and higher in the high-risk group (8.9% over 5 years; 1.9% annualized rate of SCD). However, patients predicted to be at an intermediate risk had annualized and 5-year rates of SCD that were indistinguishable from the risks of patients predicted to be at a low risk. Thus, as the authors acknowledge, the risk calculator could discriminate high-from not high-risk patients reasonably well but could not further refine risk prediction in the not high-risk group. Moreover, the C statistic of 0.70 found in this study indicates only moderate ability to discriminate between those at risk for SCD and those not at risk.
These challenges are further compounded by the distribution of patients in the high-and not high-risk groups. Although their absolute rate of sudden death is low, most events will occur in the not high-risk group simply because most patients reside in that group and the risk prediction algorithm is imperfect. Combined, patients classified at low and intermediate risk accounted for 86% of the cohort and were responsible for 51% of SCD events (21 of 41) in the complete case data set. This highlights the difficulties in stratifying risk in patients who do not manifest traditional predictors. As seen in other primary prevention indications, most of the ICDs that are implanted do not ultimately deliver a lifesaving therapy, and many people deemed not to qualify for an ICD will have events.
Risk stratification in patients with HCM is inherently imperfect and imprecise and cannot reliably determine whether any specific patient should or should not receive an ICD. Although we need to remain humble and recognize that our ability to predict the future is limited, it will, we hope, improve over time. New data on cardiac magnetic resonance measurements, 6,7 the duration and rate of NSVT, 8 and genotype continue to accumulate from clinical cohorts. The National Institutes of Healthsponsored multicenter Hypertrophic Cardiomyopathy Registry is performing a much-needed prospective observational study in a large cohort of patients with HCM to potentially confirm traditional and identify novel markers of risk and to improve strategies for stratifying patients. 9 Furthermore, advances in technology such as the subcutaneous ICD with potentially lower long-term risk will change the risk-benefit calculus for ICD therapy. Ultimately, informing patients about the limitations of medical knowledge and fully engaging them in their management will serve us all well in arriving at the best decision for each individual patient.
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